Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | POLA1 | P09884 | 1/20 | 1.00 |
| ▸ | POLD1 | P28340 | 1/20 | 1.00 |
| ▸ | TK1 | P04183 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zidovudine Triphosphate SCHEMBL23585776 | 1.00 | POLB (1.00) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL21067527 | 0.98 | POLB (0.96) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL18009254 | 0.95 | POLB (0.90) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL24705591 | 0.93 | POLB (0.87) | POLBPOLA1POLD1TK1LMNA | |
| Azidothymidine Monophosphate SCHEMBL13450790 | 0.91 | POLB (0.83) | POLBPOLA1POLD1TK1LMNA | |
| Azidothymidine Monophosphate SCHEMBL14188505 | 0.91 | POLB (0.83) | POLBPOLA1POLD1TK1LMNA | |
| Azidothymidine Monophosphate SCHEMBL15094301 | 0.91 | POLB (0.83) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL14370679 | 0.89 | POLB (0.80) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL30272183 | 0.88 | POLB (0.79) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL21473320 | 0.88 | POLB (0.79) | POLBPOLA1POLD1TK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283183-A1 | NESTED-CLICKSEQ FOR TARGETED AMPLICON AND PROVIRUS/TRANSGENE JUNCTION SEQUENCING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-09-11 | — | — | US | claimed |
| US-20240398981-A1 | NOVEL NANOPARTICLES OF ANTIRETROVIRAL DRUGS, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS | Universite Paris-Saclay (FR) | 2024-12-05 | — | — | US | claimed |
| US-20240390479-A1 | TAIL-CONJUGATED RNAS | TIBA BIOTECH (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024238925-A2 | COMPOSITIONS AND METHODS FOR INDUCING VIRAL MIMICRY IN CANCER CELLS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2023212213-A1 | TAIL-CONJUGATED RNAS | TIBA BIOTECH (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230304107-A1 | Tiled ClickSeq for Targeted Virus Whole Genome Sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-09-28 | — | — | US | claimed |
| US-20230272464-A1 | MODIFIED NUCLEOTIDES AND METHODS FOR DNA AND RNA POLYMERIZATION AND SEQUENCING | SENA RES INCORPORATED (US) | 2023-08-31 | — | — | US | claimed |
| CN-115282259-A | Oral spray preparation based on virus blocking agent and application thereof | 康码（上海）生物科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| US-20220307066-A1 | AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY | UNIVERSITY OF WASHINGTON (US) | 2022-09-29 | — | — | US | claimed |
| EP-2824189-B1 | COMPOSITION FOR HOT-START REVERSE TRANSCRIPTION REACTION OR HOT-START REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION | BIONEER CORP (KR) | 2018-01-31 | — | — | EP | claimed |
| US-20260139294-A1 | DEVELOPMENT OF A RAPID ENZYMATIC ASSAY FOR ANTIRETROVIRAL DRUG MONITORING USING CRISPR REPORTERS | UNIVERSITY OF WASHINGTON (US) | 2026-05-21 | — | — | US | disclosed |
| US-12448647-B2 | Methods of monitoring a reaction | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12441751-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250283183-A1 | NESTED-CLICKSEQ FOR TARGETED AMPLICON AND PROVIRUS/TRANSGENE JUNCTION SEQUENCING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-09-11 | — | — | US | disclosed |
| US-12404296-B2 | Poly(A)-ClickSeq click-chemistry for next generation 3-end sequencing without RNA enrichment or fragmentation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-09-02 | — | — | US | disclosed |
| CN-114230571-A | Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof | 无限药品股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-108776747-B | Method for estimating drug effect of zidovudine | 余鹏 | 2022-02-01 | — | — | CN | disclosed |
| US-20210008104-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | disclosed |
| EP-3664811-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032749-A2 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441751-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | POLB 4356/4885POLA1 4692/4885POLD1 4747/4885 |
| US-20260139294-A1 | DEVELOPMENT OF A RAPID ENZYMATIC ASSAY FOR ANTIRETROVIRAL DRUG MONITORING USING CRISPR REPORTERS | APOBEC3A, RNGTT, APOBEC3B | POLB 68/4885POLA1 25/4885POLD1 257/4885 |
| US-12448647-B2 | Methods of monitoring a reaction | EWSR1, MAVS, TIAL1 | POLB 1826/4885POLA1 3956/4885POLD1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.